Sulfacetamide sodium ophthalmic Alternatives Compared
Sulfacetamide sodium ophthalmic | Lotemax (loteprednol) | Alrex (loteprednol) |
|
---|
Sulfacetamide sodium ophthalmic | Lotemax (loteprednol) | Alrex (loteprednol) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Conjunctivitis, Eye Conditions, Trachoma. Sulfacetamide sodium ophthalmic may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Conjunctivitis, Iritis, Cyclitis, Keratitis, Postoperative Ocular Inflammation, Rosacea, Seasonal Allergic Conjunctivitis. Lotemax may also be used for purposes not listed in this... View more |
Prescription only
Prescribed for Conjunctivitis, Iritis, Cyclitis, Keratitis, Postoperative Ocular Inflammation, Rosacea, Seasonal Allergic Conjunctivitis. Alrex may also be used for purposes not listed in this... View more |
Related suggestions |
|||||||||||||||||||||||
More about Sulfacetamide sodium ophthalmic | More about Lotemax (loteprednol) | More about Alrex (loteprednol) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Sulfacetamide sodium ophthalmic has an average rating of 8.3 out of 10 from a total of 4 ratings on Drugs.com. 75% of reviewers reported a positive effect, while 0% reported a negative effect. |
Lotemax has an average rating of 6.4 out of 10 from a total of 16 ratings on Drugs.com. 56% of reviewers reported a positive effect, while 38% reported a negative effect. |
Alrex has an average rating of 6.7 out of 10 from a total of 3 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 33% reported a negative effect. |
||||||||||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Lotemax side effects |
View all Alrex side effects |
|||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
Lower cost generic |
||||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
|
View all Lotemax prices |
View all Alrex prices |
||||||||||||||||||||||||
Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
AK-Sulf, Bleph-10, Cetamide | Other loteprednol brands include: Alrex, Eysuvis, Inveltys, Lotemax SM | Other loteprednol brands include: Eysuvis, Inveltys, Lotemax, Lotemax SM | ||||||||||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 1 drugs are known to interact with Sulfacetamide sodium ophthalmic:
|
A total of 42 drugs are known to interact with Lotemax:
|
A total of 42 drugs are known to interact with Alrex:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
July 21, 1946 |
April 15, 2011 |
N/A |
||||||||||||||||||||||||
WADA Class View classifications | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient Resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.